Welcome to our dedicated page for Neximmune news (Ticker: NEXI), a resource for investors and traders seeking the latest updates and insights on Neximmune stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Neximmune's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Neximmune's position in the market.
NexImmune, a clinical-stage biotechnology company, announced a collaboration with Rutgers University to develop immunotherapies targeting immune checkpoint proteins for neuroendocrine tumors. Dr. Steven K. Libutti will lead the research aimed at addressing the rising incidence of these tumors in the U.S. using NexImmune's AIM ACT platform, which employs nanoparticles to enhance T cell responses. The company is also advancing its lead candidates, NEXI-001 and NEXI-002, currently in clinical trials for treating relapsed AML and multiple myeloma.
NexImmune, a clinical-stage biotechnology company, announced CEO Scott Carmer's participation in the LLS TAP panel discussion on January 21, 2022, at 12:00 p.m. ET. The discussion focuses on advancements in next-generation cell therapies. NexImmune has received ongoing support from the Leukemia & Lymphoma Society, benefiting from investments since 2017 to enhance its Phase 1/2 studies in treating blood cancers. Their proprietary AIM™ nanoparticle technology aims to generate specific and durable immune responses, with lead programs, NEXI-001 and NEXI-002, currently in clinical trials.
NexImmune, Inc. (Nasdaq: NEXI) announces the establishment of its Autoimmune and Infectious Disease Scientific Advisory Board (AI & ID SAB), featuring notable experts in immunology and T cell biology. This strategic move aims to enhance the company's AIM nanotechnology platform, which directs antigen-specific T cells for targeted immune responses. Jerry Zeldis, EVP of R&D, emphasized the board's role in refining decisions as NexImmune expands its therapeutic pipeline, especially for its lead programs NEXI-001 and NEXI-002, both in Phase 1/2 clinical trials.
NexImmune, Inc. (Nasdaq: NEXI) announced preliminary Phase 1/2 results for NEXI-002, a novel immunotherapy for relapsed/refractory multiple myeloma presented at the 63rd ASH Annual Meeting. The study involved patients with an average of 7.6 prior therapy lines, displaying a favorable safety profile with no severe toxicities. Early data suggests NEXI-002 shows immunologic activity, with a stable disease duration of 2 to 3.5 months in patients. These results encourage ongoing evaluations and potential applications in lower-burden plasma cell dyscrasias.
NexImmune (Nasdaq: NEXI) reported a net loss of $14.6M for Q3 2021, translating to a GAAP loss per share of $0.65. Cash reserves declined to $93.2M from $102.8M in Q2 2021, expected to last through Q4 2022. The company continues to advance its Phase 1/2 trials for NEXI-001 and NEXI-002, with updates forthcoming in 2022. Collaborations with Yale University on Type 1 Diabetes using AIM INJ nanoparticles signify strategic expansion. R&D expenses surged to $11.3M, reflecting higher trial costs and personnel expenses.
NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology firm, announced plans to report its third quarter financial results and provide a corporate update on November 12, 2021, before market open. The press release will be accessible on the company's investor website. NexImmune is focused on innovative immunotherapy development utilizing its AIM™ nanoparticle technology, with lead programs NEXI-001 and NEXI-002 currently in Phase 1/2 trials targeting relapsed AML and multiple myeloma, respectively.
Summary not available.
NexImmune, a clinical-stage biotechnology company (Nasdaq: NEXI), announced that CEO Scott Carmer will present at the 2021 Cantor Virtual Global Healthcare Conference on September 29, 2021, at 2:00 PM ET. The event will be accessible through NexImmune's Investor Relations page, with a replay available for 90 days. NexImmune focuses on immunotherapy leveraging T cells for targeted immune responses, utilizing a proprietary AIM™ nanoparticle technology. The company’s lead programs, NEXI-001 and NEXI-002, are in Phase 1/2 trials for relapsed AML and multiple myeloma, respectively.
NexImmune, a clinical-stage biotechnology company, announced that CEO Scott Carmer will participate in a fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on September 10, 2021, at 1:15 p.m. ET. The chat will be available via webcast on the company's Investor Relations page, with a replay lasting 30 days. NexImmune focuses on immunotherapy using its AIM nanoparticle technology to generate targeted immune responses through T cells. Its lead programs, NEXI-001 and NEXI-002, are in Phase 1/2 trials for treating relapsed AML and refractory multiple myeloma.
NexImmune, Inc. (NEXI) announced significant clinical developments, including its first solid tumor indication targeting HPV-associated malignancies. During Q2 2021, NexImmune reported a cash position of $102.8M, down from $118.1M in Q1. The company recorded a net loss of $12.2M, equating to a GAAP loss per share of $0.54. R&D expenses rose to $8.1M, reflecting ongoing clinical trials. The company anticipates completing enrollment in its Phase I/II trials for NEXI-001 and NEXI-002 and revealing additional data at upcoming scientific conferences.